v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Jun. 27, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 4,064 $ 9,852
Short-term investments 0 253
Accounts receivable, less allowances of $148 and $147 9,451 8,900
Inventories 5,627 5,425
Contract assets, net 1,688 1,666
Other current assets 2,536 2,612
Total current assets 23,365 28,707
Property, plant and equipment, net 10,755 10,565
Acquisition-related intangible assets, net 18,606 15,838
Other assets 5,616 5,871
Goodwill 54,832 49,362
Total assets 113,174 110,343
Current liabilities:    
Short-term obligations and current maturities of long-term obligations 3,368 3,533
Accounts payable 3,268 3,622
Accrued payroll and employee benefits 1,694 1,995
Contract liabilities 2,918 2,710
Other accrued expenses 3,823 3,329
Total current liabilities 15,069 15,189
Deferred income taxes 1,579 1,493
Other long-term liabilities 4,538 4,273
Long-term obligations 39,181 35,852
Redeemable noncontrolling interest 121 122
Thermo Fisher Scientific Inc. shareholders’ equity:    
Preferred stock, $100 par value, 50,000 shares authorized; none issued 0 0
Common stock, $1 par value, 1,200,000,000 shares authorized; 445,673,899 and 445,160,301 shares issued 446 445
Capital in excess of par value 18,870 18,563
Retained earnings 62,194 59,156
Treasury stock at cost, 75,926,613 and 68,938,831 shares (26,370) (22,309)
Accumulated other comprehensive income/(loss) (2,460) (2,448)
Total Thermo Fisher Scientific Inc. shareholders’ equity 52,679 53,407
Noncontrolling interests 7 7
Total equity 52,686 53,415
Total liabilities, redeemable noncontrolling interest and equity $ 113,174 $ 110,343